Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by HighSkies2019on Dec 18, 2021 1:46pm

270 Views

Post# 34243601

Any Chance Next Week !!!

With the TSX finally accepting the terms of the private placement ... Any chance that we could get a nr next week of a start date for clinical trial...or is there other issues that need to be cleared ... such as uplisting to OTCB to get us poised before news of start date....Getting this news on friday after trading hours is making me WANT to think that monday morning we could see a halt or nr of sort re start date.... I see other conditions of the term agreement is $50K daily trading volume and 15M market cap .... gives us approx 40 trading days to see movent upwards ... trying not to get over excited too many disappointments thus far...glta

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario